March 23 Movement & Gilead Sciences

March 23 Movement: The March 23 Movement rebel group controls parts of Democratic Republic of the Congo — North Kivu and Democratic Republic of the Congo — South Kivu provinces, including Democratic Republic of the Congo — Goma, where Ebola cases have been confirmed. Their presence complicates humanitarian access and coordination of the response.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

March 23 Movement: The March 23 Movement>>>, a rebel group, controls parts of North and South Kivu provinces in the Democratic Republic of the Congo>>>, complicating Ebola response efforts due to insecurity and lack of communication with the government.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

March 23 Movement: The March 23 Movement, backed by Rwanda, controls key cities in Democratic Republic of the Congo — North Kivu and Democratic Republic of the Congo — South Kivu, further hindering Ebola containment efforts and contributing to the humanitarian crisis.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

March 23 Movement: The March 23 Movement, a Rwanda-backed rebel group, controls parts of eastern Democratic Republic of the Congo, further complicating the Ebola response due to ongoing conflict and instability.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.